Why has ESLA's EPS stagnated since early 2024?

The EPS of ESLA (Estrella Immunopharma) has not shown significant growth since early 2024, and there are several reasons for this stagnation: 1. **Financial Performance Issues**: Estrella Immunopharma has been reporting negative EPS, with the most recent report period ending on March 31, 2024, showing a diluted EPS of -$0.01. This indicates that the company has not been profitable during this period. |code|Ticker|Name|Date|Diluted EPS YoY|Diluted EPS|market_code| |---|---|---|---|---|---|---| |ESLA|ESLA.O|Estrella|2024 Q1|94.81503058549373|-1.78|186| |ESLA|ESLA.O|Estrella|2024 Q2|99.8162890385793|-0.03|186| |ESLA|ESLA.O|Estrella|2024 Q3|99.87699876998771|-0.01|186| 2. **Revenue Decline**: The company has not reported any revenue for the third quarter of 2024. This lack of revenue contributes significantly to the negative EPS, as there is no income to cover the expenses and generate profit. 3. **Increased Expenses**: Estrella Immunopharma has seen an increase in research and development expenses, with the quarter ending on September 30, 2024, reporting $2,826,000 in such expenses, up from $483,466 in the same quarter the previous year. These increased expenses, coupled with no revenue to offset them, lead to a higher net loss and thus a stagnating EPS. 4. **Cash Flow Issues**: The company has experienced a net cash used in operating activities of $2,217,460 for the quarter ending on September 30, 2024. This negative cash flow is a result of the net loss and an increase in prepaid expenses related to clinical trial services, which can put additional strain on the company's financial health and make it difficult to invest in growth opportunities. 5. **Business Combination Impact**: The company completed a business combination with TradeUP Acquisition Corp. on September 29, 2023, raising net proceeds of approximately $20.1 million. While this capital raise may have provided some financial breathing room, it does not appear to have led to immediate EPS growth, as the EPS continued to stagnate. In summary, ESLA's EPS stagnation since early 2024 is primarily due to the company's financial performance issues, lack of revenue, increased expenses, cash flow challenges, and the impact of business combination. These factors combined have created a difficult environment for the company to generate earnings growth in the near term.